참고문헌
- Old LJ: Tumor immunology: the first century. Curr Opin Immunol 4;603-607, 1992 https://doi.org/10.1016/0952-7915(92)90034-C
- Minev BR, Chavez FL, Mitchell MS: Cancer vaccines: novel approaches and new promise. Pharmacol Ther 81;121-139, 1999 https://doi.org/10.1016/S0163-7258(98)00039-4
- Moingeon P: Cancer vaccines. Vaccine 19;1305-1326, 2001 https://doi.org/10.1016/S0264-410X(00)00372-8
- Hernando JJ, Park TW, Kubler K, Offergeld R, Schlebusch H, Bauknecht T: Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial. Cancer Immunol Immunother 51;45-52, 2002 https://doi.org/10.1007/s00262-001-0255-1
- Jennings GT, Bachmann MF: Immunotherapies: cause for measured optimism. Drug Discov Today 7;994-996, 2002 https://doi.org/10.1016/S1359-6446(02)02443-1
- Chang AE, Redman BG, Whitfield JR, Nickoloff BJ, Braun TM, Lee PP, Geiger JD, Mule JJ: A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res 8;1021-1032, 2002
- Rapp M, Ozcan Z, Steiger HJ, Wernet P, Sabel MC, Sorg RV:Cellular immunity of patients with malignant glioma: prerequisites for dendritic cell vaccination immunotherapy. J Neurosurg 105;41-50, 2006 https://doi.org/10.3171/jns.2006.105.1.41
- Kim R, Emi M, Tanabe K, Arihiro K: Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 66;5527-5536, 2006 https://doi.org/10.1158/0008-5472.CAN-05-4128
- Malmberg KJ: Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape? Cancer Immunol Immunother 53;879-892, 2004
- Lindauer M, Stanislawski T, Haussler A, Antunes E, Cellary A, Huber C, Theobald M: The molecular basis of cancer immunotherapy by cytotoxic T lymphocytes. J Mol Med 76;32-47, 1998 https://doi.org/10.1007/s109-1998-8102-9
- Perez-Diez A, Marincola FM: Immunotherapy against antigenic tumors: a game with a lot of players. Cell Mol Life Sci 59;230-240, 2002 https://doi.org/10.1007/s00018-002-8419-5
- McKenzie IF, Apostolopoulos V, Plebanski M, Pietersz GA, Loveland BE: Aspects of cancer immunotherapy. Immunol Cell Biol 81;79-85, 2003 https://doi.org/10.1046/j.0818-9641.2002.01140.x
- Morris EC, Bendle GM, Stauss HJ: Perspects for immunotherapy of malignant disease. Clin Exp Immunol 131;1-7, 2003 https://doi.org/10.1046/j.1365-2249.2003.02055.x
- Buchanan KL, Murphy JW: Kinetics of cellular infiltration and cytokine production during the efferent phase of a delayedtype hypersensitivity reaction. Immunology 90;189-197, 1997 https://doi.org/10.1046/j.1365-2567.1997.00144.x
- Kobayashi K, Kaneda K, Kasama T: Immunopathogenesis of delayed-type hypersensitivity. Microsc Res Tech 53;241-245, 2001 https://doi.org/10.1002/jemt.1090
- Roychowdhury S, Svensson CK: Mechanisms of drug-induced delayed-type hypersensitivity reactions in the skin. AAPS J 7;E834-E846, 2005 https://doi.org/10.1208/aapsj070480
- Dhabhar FS, McEwen BS: Stress-induced enhancement of antigen-specific cell-mediated immunity. J Immunol 156;2608-2615, 1996
- Ridolfi R, Petrini M, Fiammenghi L, Stefanelli M, Ridolfi L, Ballardini M, Migliori G, Riccobon A: Improved overall survival in dendritic cell vaccination-induced immunoreactive sub group of advanced melanoma patients. J Transl Med 4;36, 2006 https://doi.org/10.1186/1479-5876-4-36
- Toura I, Kawano T, Akutsu Y, Nakayama T, Ochiai T, Taniguchi M: Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide. J Immunol 163;2387-2391, 1999
- Danna EA, Sinha P, Gilbert M, Clements VK, Pulaski BA, Ostrand-Rosenberg S: Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res 64;2205-2211, 2004 https://doi.org/10.1158/0008-5472.CAN-03-2646
- Salvadori S, Martinelli G, Zier K: Resection of solid tumors reverses T cell defects and restores protective immunity. J Immunol 164;2214-2220, 2000 https://doi.org/10.4049/jimmunol.164.4.2214
- Larmonier N, Marron M, Zeng Y, Cantrell J, Romanoski A, Sepassi M, Thompson S, Chen X, Andreansky S, Katsanis E:Tumor-derived CD4(+) CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. Cancer Immunol Immunother 13 [Epub]; 2006
- Horiguchi S, Petersson M, Nakazawa T, Kanda M, Zea AH, Ochoa AC, Kiessling R: Primary chemically induced tumors induce profound immunosuppression concomitant with apoptosis and alterations in signal transduction in T cells and NK cells. Cancer Res 59;2950-2956, 1999
- Barbieri C, Fujisawa MM, Yasuda CL, Metze IL, Oliveira EC, Santos LM, Lopes LR, Andreollo NA: Effect of surgical treatment on the cellular immune response of gastric cancer patients. Braz J Med Biol Res 36;339-345, 2003
- Kempuraj D, Devi RS, Madhappan B, Conti P, Nazer MY, Christodoulou S, Reginald J, Suthinthirarajan N, Namasivayam A: T lymphocyte subsets and immunoglobulins in intracranial tumor patients before and after treatment, and based on histological type of tumors. Int J Immunopathol Pharmacol 17;57-64, 2004